X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with Religare Enterprises - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs RELIGARE ENT. - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

RELIGARE ENT. 
   Change

Promoted by Mr. Malvinder Mohan Singh and Mr. Shivinder Mohan Singh , Religare Enterprises is a financial services company, offering a wide range of financial products and services targeted at retail investors, high net worth individuals and corporat... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES RELIGARE ENT. INDOCO REMEDIES/
RELIGARE ENT.
 
P/E (TTM) x 21.9 5.3 413.3% View Chart
P/BV x 2.6 0.2 1,129.9% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 INDOCO REMEDIES   RELIGARE ENT.
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
RELIGARE ENT.
Mar-16
INDOCO REMEDIES/
RELIGARE ENT.
5-Yr Chart
Click to enlarge
High Rs360395 91.2%   
Low Rs249256 97.3%   
Sales per share (Unadj.) Rs119.0218.0 54.6%  
Earnings per share (Unadj.) Rs8.4-2.3 -356.8%  
Cash flow per share (Unadj.) Rs15.2-0.6 -2,624.9%  
Dividends per share (Unadj.) Rs1.600-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs70.7190.0 37.2%  
Shares outstanding (eoy) m92.15203.33 45.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.61.5 171.5%   
Avg P/E ratio x36.4-138.9 -26.2%  
P/CF ratio (eoy) x20.0-561.0 -3.6%  
Price / Book Value ratio x4.31.7 251.6%  
Dividend payout %19.10-   
Avg Mkt Cap Rs m28,08366,184 42.4%   
No. of employees `0006.0NA-   
Total wages/salary Rs m2,1679,336 23.2%   
Avg. sales/employee Rs Th1,817.0NM-  
Avg. wages/employee Rs Th359.0NM-  
Avg. net profit/employee Rs Th127.7NM-  
INCOME DATA
Net Sales Rs m10,96844,318 24.7%  
Other income Rs m40709 5.6%   
Total revenues Rs m11,00745,026 24.4%   
Gross profit Rs m1,56523,723 6.6%  
Depreciation Rs m633359 176.5%   
Interest Rs m6218,721 0.3%   
Profit before tax Rs m9095,351 17.0%   
Minority Interest Rs m0-1,085 0.0%   
Prior Period Items Rs m06 0.0%   
Extraordinary Inc (Exp) Rs m0-2,533 0.0%   
Tax Rs m1392,215 6.3%   
Profit after tax Rs m771-477 -161.7%  
Gross profit margin %14.353.5 26.7%  
Effective tax rate %15.341.4 36.8%   
Net profit margin %7.0-1.1 -653.4%  
BALANCE SHEET DATA
Current assets Rs m5,72594,957 6.0%   
Current liabilities Rs m5,454103,036 5.3%   
Net working cap to sales %2.5-18.2 -13.5%  
Current ratio x1.00.9 113.9%  
Inventory Days Days625 1,308.1%  
Debtors Days Days7238 187.9%  
Net fixed assets Rs m5,30717,890 29.7%   
Share capital Rs m1842,033 9.1%   
"Free" reserves Rs m6,33133,999 18.6%   
Net worth Rs m6,51638,629 16.9%   
Long term debt Rs m1,323118,583 1.1%   
Total assets Rs m11,970274,293 4.4%  
Interest coverage x15.61.3 1,216.7%   
Debt to equity ratio x0.23.1 6.6%  
Sales to assets ratio x0.90.2 567.1%   
Return on assets %7.06.7 104.6%  
Return on equity %11.8-1.2 -958.8%  
Return on capital %12.413.0 95.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5070-   
Fx outflow Rs m1,14112 9,672.9%   
Net fx Rs m3,366-12 -28,521.2%   
CASH FLOW
From Operations Rs m886-21,540 -4.1%  
From Investments Rs m-1,7065,149 -33.1%  
From Financial Activity Rs m1,31618,531 7.1%  
Net Cashflow Rs m4972,139 23.2%  

Share Holding

Indian Promoters % 59.2 50.9 116.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 0.9 1,388.9%  
FIIs % 6.0 15.3 39.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 32.9 68.1%  
Shareholders   12,805 26,518 48.3%  
Pledged promoter(s) holding % 0.0 68.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   IL&FS INV. MANAGERS  REDINGTON (INDIA)  GEOJIT BNP PARIBAS  REPCO HOME  TIMKEN INDIA  



Today's Market

Indian Indices Trade on a Negative Note; Sensex Down Over 160 Points(12:30 pm)

After opening the day marginally higher, share markets in India witnessed selling pressure and are presently trading on a negative note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)

May 9, 2018

PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


May 21, 2018 02:23 PM

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS